Genetic testing of gastrointestinal cancer patients prior to starting chemotherapy proved feasible in a prospective study and ...

A new study published in JCO Precision Oncology has identified a relatively simple method to predict the cancer patients most likely to develop severe toxi | Cancer ...

In these 1100 patients, there were about 85 patients that were heterozygous carriers of a DPYD variant. What we did, we compared these two groups with each other, but before the DPYD carriers started, ...

DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial. Authors: Valérie Boige, Marc ...

DPD deficiency screening using the YourGene DPYD kit has been implemented in order to identify those patients at increased risk of toxicity and reduce the likelihood of adverse drug reactions.

DPYD tests work to identify patients with dihydropyrimidine dehydrogenase deficiency, which can cause them to experience serious adverse reactions to capecitabine or 5-fluorouracil, also known as ...

Whereas many of the earlier studies on DPYD variation and 5-FU toxicity were focused on selected sets of variants, recently, more comprehensive mutation screenings of DPYD have been performed. In ...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of ...

Severe and life-threatening toxicity of 5-fluorouracil (5-FU) is strongly associated with a genetic polymorphism in the 5-FU metabolizing enzyme dihydropyrimidine dehydrogenase, specifically, DPYD ...

Fluorouracil is not recommended for use in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency. The Food and Drug Administration ...